Skip to main content
Erschienen in: World Journal of Surgery 7/2008

01.07.2008

Do Benign Thyroid Nodules Have Malignant Potential? An Evidence-Based Review

verfasst von: Nimmi Arora, Theresa Scognamiglio, Baixin Zhu, Thomas J. Fahey III

Erschienen in: World Journal of Surgery | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Benign thyroid tumors account for most nodular thyroid disease. Determination of whether a thyroid nodule is benign or malignant is a major clinical dilemma and underlies the decision to proceed to surgery in many patients. Although the accuracy of thyroid nodule fine-needle aspiration (FNA) has reduced the need for surgery over the years, questions regarding how to follow FNA-designated benign nodules remain unresolved. This is true at least in part because of uncertainty over whether some benign nodules harbor malignant potential.

Methods

An evidence-based review of recent clinical, pathologic, and molecular data is presented. A summary of data and observations from our own experience is also provided.

Results

Review of our recent 10-year experience indicates that 2% of thyroid malignancies arise within a preexisting benign thyroid nodule. In addition, both cytologic and molecular tumor markers, including Gal-3, CITED1, HBME-1, Ras, RET/PTC, and PAX8/PPARγ, have been identified in some histopathologically classified benign nodules. Gene expression profiling suggests that follicular adenomas and Hürthle cell adenomas have similarities to both benign and malignant tumors, suggesting that some of these tumors are premalignant. In addition, 10% of surgically excised follicular tumors are encapsulated follicular lesions with nuclear atypia, which have been termed “well-differentiated tumors of uncertain malignant potential.” The data available suggest that these tumors could be precursors to carcinoma.

Conclusion

Some benign thyroid nodules have malignant potential. Further molecular testing of these tumors can shed light on the pathogenesis of early malignant transformation.
Literatur
1.
Zurück zum Zitat Mazzaferri EL (1981) Solitary thyroid nodule. 2. Selective approach to management. Postgrad Med 70:107–109, 112, 116PubMed Mazzaferri EL (1981) Solitary thyroid nodule. 2. Selective approach to management. Postgrad Med 70:107–109, 112, 116PubMed
2.
Zurück zum Zitat Mortensen JD, Woolner LB, Bennett WA (1955) Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 15:1270–1280PubMed Mortensen JD, Woolner LB, Bennett WA (1955) Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 15:1270–1280PubMed
3.
Zurück zum Zitat Lang W, Borrusch H, Bauer L (1988) Occult carcinomas of the thyroid: evaluation of 1,020 sequential autopsies. Am J Clin Pathol 90:72–76PubMed Lang W, Borrusch H, Bauer L (1988) Occult carcinomas of the thyroid: evaluation of 1,020 sequential autopsies. Am J Clin Pathol 90:72–76PubMed
4.
Zurück zum Zitat Rosai J, Carcangiu ML, DeLellis RA (1992) Atlas of Tumor Pathology. 3rd edition. Vol 5. Armed Forces Institute of Pathology, Washington, DC Rosai J, Carcangiu ML, DeLellis RA (1992) Atlas of Tumor Pathology. 3rd edition. Vol 5. Armed Forces Institute of Pathology, Washington, DC
5.
Zurück zum Zitat Sackett DL (1989) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S–4SPubMedCrossRef Sackett DL (1989) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2S–4SPubMedCrossRef
6.
Zurück zum Zitat Barden CB, Shister KW, Zhu B, et al (2003) Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9:1792–1800PubMed Barden CB, Shister KW, Zhu B, et al (2003) Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9:1792–1800PubMed
7.
Zurück zum Zitat Finley DJ, Arora N, Zhu B, et al (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214–3223PubMedCrossRef Finley DJ, Arora N, Zhu B, et al (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214–3223PubMedCrossRef
8.
Zurück zum Zitat Nikiforova MN, Kimura ET, Gandhi M, et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef Nikiforova MN, Kimura ET, Gandhi M, et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef
9.
Zurück zum Zitat Alexander EK, Hurwitz S, Heering JP, et al (2003) Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 138:315–318PubMed Alexander EK, Hurwitz S, Heering JP, et al (2003) Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 138:315–318PubMed
10.
Zurück zum Zitat Kuma K, Matsuzuka F, Yokozawa T, et al (1994) Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg 18:495–498PubMedCrossRef Kuma K, Matsuzuka F, Yokozawa T, et al (1994) Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg 18:495–498PubMedCrossRef
11.
Zurück zum Zitat Evans HL, Vassilopoulou-Sellin R (1998) Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 22:1512–1520PubMedCrossRef Evans HL, Vassilopoulou-Sellin R (1998) Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. Am J Surg Pathol 22:1512–1520PubMedCrossRef
12.
Zurück zum Zitat Park SH, Suh EH, Chi JG (1988) A histopathologic study on 1,095 surgically resected thyroid specimens. Jpn J Clin Oncol 18:297–302PubMed Park SH, Suh EH, Chi JG (1988) A histopathologic study on 1,095 surgically resected thyroid specimens. Jpn J Clin Oncol 18:297–302PubMed
13.
Zurück zum Zitat Pennelli N, Pennelli G, Merante Boschin I, et al (2005) Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma. Ann Ital Chir 76:219–224PubMed Pennelli N, Pennelli G, Merante Boschin I, et al (2005) Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma. Ann Ital Chir 76:219–224PubMed
14.
Zurück zum Zitat Hazard JB, Kenyon R (1954) Atypical adenoma of the thyroid. AMA Arch Pathol 58:554–563PubMed Hazard JB, Kenyon R (1954) Atypical adenoma of the thyroid. AMA Arch Pathol 58:554–563PubMed
15.
Zurück zum Zitat Vickery AL Jr (1983) Thyroid papillary carcinoma: pathological and philosophical controversies. Am J Surg Pathol 7:797–807PubMedCrossRef Vickery AL Jr (1983) Thyroid papillary carcinoma: pathological and philosophical controversies. Am J Surg Pathol 7:797–807PubMedCrossRef
16.
Zurück zum Zitat Chan JK (2002) Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 117:16–18PubMedCrossRef Chan JK (2002) Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 117:16–18PubMedCrossRef
17.
Zurück zum Zitat Franc B, de la Salmoniere P, Lange F, et al (2003) Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 34:1092–1100PubMedCrossRef Franc B, de la Salmoniere P, Lange F, et al (2003) Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 34:1092–1100PubMedCrossRef
18.
Zurück zum Zitat Lloyd RV, Erickson LA, Casey MB, et al (2004) Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–1340PubMedCrossRef Lloyd RV, Erickson LA, Casey MB, et al (2004) Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–1340PubMedCrossRef
19.
Zurück zum Zitat Saxen E, Franssila K, Bjarnason O, et al (1978) Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand [A] 86A:483–486 Saxen E, Franssila K, Bjarnason O, et al (1978) Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand [A] 86A:483–486
20.
Zurück zum Zitat Hirokawa M, Carney JA, Goellner JR, et al (2002) Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26:1508–1514PubMedCrossRef Hirokawa M, Carney JA, Goellner JR, et al (2002) Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26:1508–1514PubMedCrossRef
21.
Zurück zum Zitat Williams ED (2000) Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8:181–183PubMedCrossRef Williams ED (2000) Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8:181–183PubMedCrossRef
22.
Zurück zum Zitat Mai KT, Landry DC, Thomas J, et al (2001) Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma. Histopathology 39:25–32PubMedCrossRef Mai KT, Landry DC, Thomas J, et al (2001) Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma. Histopathology 39:25–32PubMedCrossRef
23.
Zurück zum Zitat Liu J, Singh B, Tallini G, et al (2006) Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107:1255–1264PubMedCrossRef Liu J, Singh B, Tallini G, et al (2006) Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107:1255–1264PubMedCrossRef
24.
Zurück zum Zitat Bartolazzi A, Gasbarri A, Papotti M, et al (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644–1650PubMedCrossRef Bartolazzi A, Gasbarri A, Papotti M, et al (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644–1650PubMedCrossRef
25.
Zurück zum Zitat Prasad ML, Pellegata NS, Huang Y, et al (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, et al (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57PubMedCrossRef
26.
Zurück zum Zitat Scognamiglio T, Hyjek E, Kao J, et al (2006) Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708PubMedCrossRef Scognamiglio T, Hyjek E, Kao J, et al (2006) Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708PubMedCrossRef
27.
Zurück zum Zitat Park YJ, Kwak SH, Kim DC, et al (2007) Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22:621–628PubMed Park YJ, Kwak SH, Kim DC, et al (2007) Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22:621–628PubMed
28.
Zurück zum Zitat Beesley MF, McLaren KM (2002) Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 41:236–243PubMedCrossRef Beesley MF, McLaren KM (2002) Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 41:236–243PubMedCrossRef
29.
Zurück zum Zitat de Matos PS, Ferreira AP, de Oliveira Facuri F, et al (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47:391–401PubMedCrossRef de Matos PS, Ferreira AP, de Oliveira Facuri F, et al (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47:391–401PubMedCrossRef
30.
Zurück zum Zitat Cheung CC, Ezzat S, Freeman JL, et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338–342PubMedCrossRef Cheung CC, Ezzat S, Freeman JL, et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338–342PubMedCrossRef
31.
Zurück zum Zitat Erkilic S, Aydin A, Kocer NE (2002) Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol 13:207–211PubMedCrossRef Erkilic S, Aydin A, Kocer NE (2002) Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol 13:207–211PubMedCrossRef
32.
Zurück zum Zitat Lam KY, Lui MC, Lo CY (2001) Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 27:631–635PubMedCrossRef Lam KY, Lui MC, Lo CY (2001) Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 27:631–635PubMedCrossRef
33.
Zurück zum Zitat Nasr MR, Mukhopadhyay S, Zhang S, et al (2006) Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19:1631–1637PubMedCrossRef Nasr MR, Mukhopadhyay S, Zhang S, et al (2006) Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19:1631–1637PubMedCrossRef
34.
Zurück zum Zitat Sahoo S, Hoda SA, Rosai J, et al (2001) Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 116:696–702PubMedCrossRef Sahoo S, Hoda SA, Rosai J, et al (2001) Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 116:696–702PubMedCrossRef
35.
Zurück zum Zitat Aron M, Kapila K, Verma K (2006) Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J Pathol Microbiol 49:376–380PubMed Aron M, Kapila K, Verma K (2006) Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J Pathol Microbiol 49:376–380PubMed
36.
Zurück zum Zitat Mehrotra P, Okpokam A, Bouhaidar R, et al (2004) Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45:493–500PubMedCrossRef Mehrotra P, Okpokam A, Bouhaidar R, et al (2004) Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45:493–500PubMedCrossRef
37.
Zurück zum Zitat Papotti M, Rodriguez J, De Pompa R, et al (2005) Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541–546PubMedCrossRef Papotti M, Rodriguez J, De Pompa R, et al (2005) Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541–546PubMedCrossRef
38.
Zurück zum Zitat Fukushima T, Suzuki S, Mashiko M, et al (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455–6457PubMedCrossRef Fukushima T, Suzuki S, Mashiko M, et al (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455–6457PubMedCrossRef
39.
Zurück zum Zitat Kimura ET, Nikiforova MN, Zhu Z, et al (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMed Kimura ET, Nikiforova MN, Zhu Z, et al (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMed
40.
Zurück zum Zitat Xu X, Quiros RM, Gattuso P, et al (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561–4567PubMed Xu X, Quiros RM, Gattuso P, et al (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561–4567PubMed
41.
Zurück zum Zitat Kebebew E, Weng J, Bauer J, et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466–470PubMedCrossRef Kebebew E, Weng J, Bauer J, et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466–470PubMedCrossRef
42.
Zurück zum Zitat Lee JH, Lee ES, Kim YS (2007) Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38–46PubMedCrossRef Lee JH, Lee ES, Kim YS (2007) Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38–46PubMedCrossRef
43.
Zurück zum Zitat Ishizaka Y, Kobayashi S, Ushijima T, et al (1991) Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 6:1667–1672PubMed Ishizaka Y, Kobayashi S, Ushijima T, et al (1991) Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 6:1667–1672PubMed
44.
Zurück zum Zitat Chua EL, Wu WM, Tran KT, et al (2000) Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab 85:2733–2739PubMedCrossRef Chua EL, Wu WM, Tran KT, et al (2000) Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab 85:2733–2739PubMedCrossRef
45.
Zurück zum Zitat Learoyd DL, Messina M, Zedenius J, et al (1998) RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J Clin Endocrinol Metab 83:3631–3635PubMedCrossRef Learoyd DL, Messina M, Zedenius J, et al (1998) RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J Clin Endocrinol Metab 83:3631–3635PubMedCrossRef
46.
Zurück zum Zitat Santoro M, Papotti M, Chiappetta G, et al (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–379PubMedCrossRef Santoro M, Papotti M, Chiappetta G, et al (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–379PubMedCrossRef
47.
Zurück zum Zitat Tallini G, Santoro M, Helie M, et al (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287–294PubMed Tallini G, Santoro M, Helie M, et al (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287–294PubMed
48.
Zurück zum Zitat Capella G, Matias-Guiu X, Ampudia X, et al (1996) Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5:45–52PubMedCrossRef Capella G, Matias-Guiu X, Ampudia X, et al (1996) Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5:45–52PubMedCrossRef
49.
Zurück zum Zitat Garcia-Rostan G, Zhao H, Camp RL, et al (2003) Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226–3235PubMedCrossRef Garcia-Rostan G, Zhao H, Camp RL, et al (2003) Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226–3235PubMedCrossRef
50.
Zurück zum Zitat Karga H, Lee JK, Vickery AL Jr, et al (1991) Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832–836PubMedCrossRef Karga H, Lee JK, Vickery AL Jr, et al (1991) Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832–836PubMedCrossRef
51.
Zurück zum Zitat Lemoine NR, Mayall ES, Wyllie FS, et al (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159–164PubMed Lemoine NR, Mayall ES, Wyllie FS, et al (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159–164PubMed
52.
Zurück zum Zitat Liu RT, Hou CY, You HL, et al (2004) Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14:616–621PubMedCrossRef Liu RT, Hou CY, You HL, et al (2004) Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14:616–621PubMedCrossRef
53.
Zurück zum Zitat Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–1479PubMed Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–1479PubMed
54.
Zurück zum Zitat Vasko V, Ferrand M, Di Cristofaro J, et al (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745–2752PubMedCrossRef Vasko V, Ferrand M, Di Cristofaro J, et al (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745–2752PubMedCrossRef
55.
Zurück zum Zitat Kroll TG, Sarraf P, Pecciarini L, et al (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289:1357–1360PubMedCrossRef Kroll TG, Sarraf P, Pecciarini L, et al (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289:1357–1360PubMedCrossRef
56.
Zurück zum Zitat Dwight T, Thoppe SR, Foukakis T, et al (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88:4440–4445PubMedCrossRef Dwight T, Thoppe SR, Foukakis T, et al (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88:4440–4445PubMedCrossRef
57.
Zurück zum Zitat Lacroix L, Lazar V, Michiels S, et al (2005) Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223–231PubMed Lacroix L, Lazar V, Michiels S, et al (2005) Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223–231PubMed
58.
Zurück zum Zitat Marques AR, Espadinha C, Catarino AL, et al (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947–3952PubMedCrossRef Marques AR, Espadinha C, Catarino AL, et al (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947–3952PubMedCrossRef
59.
Zurück zum Zitat Nikiforova MN, Biddinger PW, Caudill CM, et al (2002) PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016–1023PubMedCrossRef Nikiforova MN, Biddinger PW, Caudill CM, et al (2002) PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016–1023PubMedCrossRef
60.
Zurück zum Zitat Castro P, Rebocho AP, Soares RJ, et al (2006) PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–220PubMedCrossRef Castro P, Rebocho AP, Soares RJ, et al (2006) PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213–220PubMedCrossRef
61.
Zurück zum Zitat Elisei R, Romei C, Vorontsova T, et al (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 86:3211–3216PubMedCrossRef Elisei R, Romei C, Vorontsova T, et al (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 86:3211–3216PubMedCrossRef
62.
Zurück zum Zitat Cerilli LA, Mills SE, Rumpel CA, et al (2002) Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol 118:186–193PubMedCrossRef Cerilli LA, Mills SE, Rumpel CA, et al (2002) Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol 118:186–193PubMedCrossRef
63.
Zurück zum Zitat Fusco A, Chiappetta G, Hui P, et al (2002) Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160:2157–2167PubMed Fusco A, Chiappetta G, Hui P, et al (2002) Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160:2157–2167PubMed
64.
Zurück zum Zitat Oyama T, Suzuki T, Hara F, et al (1995) N-ras mutation of thyroid tumor with special reference to the follicular type. Pathol Int 45:45–50PubMed Oyama T, Suzuki T, Hara F, et al (1995) N-ras mutation of thyroid tumor with special reference to the follicular type. Pathol Int 45:45–50PubMed
65.
Zurück zum Zitat Esapa CT, Johnson SJ, Kendall-Taylor P, et al (1999) Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50:529–535CrossRef Esapa CT, Johnson SJ, Kendall-Taylor P, et al (1999) Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50:529–535CrossRef
66.
Zurück zum Zitat Nikiforova MN, Lynch RA, Biddinger PW, et al (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–2326PubMedCrossRef Nikiforova MN, Lynch RA, Biddinger PW, et al (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–2326PubMedCrossRef
67.
Zurück zum Zitat Cheung L, Messina M, Gill A, et al (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354–357PubMedCrossRef Cheung L, Messina M, Gill A, et al (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354–357PubMedCrossRef
68.
Zurück zum Zitat Huang Y, Prasad M, Lemon WJ, et al (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98:15044–15049PubMedCrossRef Huang Y, Prasad M, Lemon WJ, et al (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98:15044–15049PubMedCrossRef
69.
Zurück zum Zitat Lubitz CC, Gallagher LA, Finley DJ, et al (2005) Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138:1042–1048PubMedCrossRef Lubitz CC, Gallagher LA, Finley DJ, et al (2005) Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138:1042–1048PubMedCrossRef
70.
Zurück zum Zitat Lubitz CC, Ugras SK, Kazam JJ, et al (2006) Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8:490–498PubMedCrossRef Lubitz CC, Ugras SK, Kazam JJ, et al (2006) Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8:490–498PubMedCrossRef
71.
Zurück zum Zitat Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia-a changing concept: a review focused on the thyroid gland. Endocr Rev 16:411–426PubMedCrossRef Studer H, Derwahl M (1995) Mechanisms of nonneoplastic endocrine hyperplasia-a changing concept: a review focused on the thyroid gland. Endocr Rev 16:411–426PubMedCrossRef
72.
Zurück zum Zitat Cerci C, Cerci SS, Eroglu E, et al (2007) Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med 53:157–160PubMed Cerci C, Cerci SS, Eroglu E, et al (2007) Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med 53:157–160PubMed
73.
Zurück zum Zitat Santoro M, Carlomagno F, Hay ID, et al (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517–1522PubMedCrossRef Santoro M, Carlomagno F, Hay ID, et al (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517–1522PubMedCrossRef
74.
Zurück zum Zitat Finley DJ, Zhu B, Barden CB, et al (2004) Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425–436PubMedCrossRef Finley DJ, Zhu B, Barden CB, et al (2004) Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425–436PubMedCrossRef
75.
Zurück zum Zitat Finley DJ, Lubitz CC, Wei C, et al (2005) Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15:562–568PubMedCrossRef Finley DJ, Lubitz CC, Wei C, et al (2005) Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15:562–568PubMedCrossRef
76.
Zurück zum Zitat McHenry CR, Sandoval BA (1998) Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am 7:893–910PubMed McHenry CR, Sandoval BA (1998) Management of follicular and Hurthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am 7:893–910PubMed
77.
Zurück zum Zitat Pisani T, Pantellini F, Centanni M, et al (2003) Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas. Anticancer Res 23:3323–3326PubMed Pisani T, Pantellini F, Centanni M, et al (2003) Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas. Anticancer Res 23:3323–3326PubMed
78.
Zurück zum Zitat Chen H, Nicol TL, Zeiger MA, et al (1998) Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 227:542–546PubMedCrossRef Chen H, Nicol TL, Zeiger MA, et al (1998) Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 227:542–546PubMedCrossRef
79.
Zurück zum Zitat Lopez-Penabad L, Chiu AC, Hoff AO, et al (2003) Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97:1186–1194PubMedCrossRef Lopez-Penabad L, Chiu AC, Hoff AO, et al (2003) Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97:1186–1194PubMedCrossRef
80.
Zurück zum Zitat Nascimento MC, Bisi H, Alves VA, et al (2001) Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 12:275–279PubMedCrossRef Nascimento MC, Bisi H, Alves VA, et al (2001) Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 12:275–279PubMedCrossRef
81.
Zurück zum Zitat Cheung CC, Ezzat S, Ramyar L, et al (2000) Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878–882PubMedCrossRef Cheung CC, Ezzat S, Ramyar L, et al (2000) Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85:878–882PubMedCrossRef
82.
Zurück zum Zitat Galusca B, Dumollard JM, Chambonniere ML, et al (2004) Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues: possible relationship to lymph node metastasis. Anticancer Res 24:1993–1997PubMed Galusca B, Dumollard JM, Chambonniere ML, et al (2004) Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues: possible relationship to lymph node metastasis. Anticancer Res 24:1993–1997PubMed
83.
Zurück zum Zitat Musholt PB, Imkamp F, von Wasielewski R, et al (2003) RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery 134:881–889PubMedCrossRef Musholt PB, Imkamp F, von Wasielewski R, et al (2003) RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery 134:881–889PubMedCrossRef
84.
Zurück zum Zitat Finley DJ, Zhu B, Fahey TJ 3rd (2004) Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136:1160–1168PubMedCrossRef Finley DJ, Zhu B, Fahey TJ 3rd (2004) Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136:1160–1168PubMedCrossRef
85.
Zurück zum Zitat Ashcraft MW, Van Herle AJ (1981) Management of thyroid nodules. I. History and physical examination, blood tests, x-ray tests, and ultrasonography. Head Neck Surg 3:216–230PubMedCrossRef Ashcraft MW, Van Herle AJ (1981) Management of thyroid nodules. I. History and physical examination, blood tests, x-ray tests, and ultrasonography. Head Neck Surg 3:216–230PubMedCrossRef
86.
Zurück zum Zitat de los Santos ET, Keyhani-Rofagha S, Cunningham JJ, et al (1990) Cystic thyroid nodules: the dilemma of malignant lesions. Arch Intern Med 150:1422–1427CrossRef de los Santos ET, Keyhani-Rofagha S, Cunningham JJ, et al (1990) Cystic thyroid nodules: the dilemma of malignant lesions. Arch Intern Med 150:1422–1427CrossRef
87.
Zurück zum Zitat Lin JD, Hsuen C, Chen JY, et al (2007) Cystic change in thyroid cancer. ANZ J Surg 77:450–454PubMedCrossRef Lin JD, Hsuen C, Chen JY, et al (2007) Cystic change in thyroid cancer. ANZ J Surg 77:450–454PubMedCrossRef
88.
Zurück zum Zitat Rehak NN, Oertel YC, Herp A, et al (1993) Biochemical analysis of thyroid cyst fluid obtained by fine-needle aspiration. Arch Pathol Lab Med 117:625–630 PubMed Rehak NN, Oertel YC, Herp A, et al (1993) Biochemical analysis of thyroid cyst fluid obtained by fine-needle aspiration. Arch Pathol Lab Med 117:625–630 PubMed
89.
Zurück zum Zitat Gasbarri A, Sciacchitano S, Marasco A, et al (2004) Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto’s thyroiditis. Br J Cancer 91:1096–1104PubMed Gasbarri A, Sciacchitano S, Marasco A, et al (2004) Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto’s thyroiditis. Br J Cancer 91:1096–1104PubMed
90.
Zurück zum Zitat Okayasu I, Fujiwara M, Hara Y, et al (1995) Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma: a study of surgical cases among Japanese, and white and African Americans. Cancer 76:2312–2318PubMedCrossRef Okayasu I, Fujiwara M, Hara Y, et al (1995) Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma: a study of surgical cases among Japanese, and white and African Americans. Cancer 76:2312–2318PubMedCrossRef
91.
Zurück zum Zitat Rhoden KJ, Unger K, Salvatore G, et al (2006) RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91:2414–2423PubMedCrossRef Rhoden KJ, Unger K, Salvatore G, et al (2006) RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91:2414–2423PubMedCrossRef
92.
Zurück zum Zitat Sargent R, LiVolsi V, Murphy J, et al (2006) BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr Pathol 17:235–241PubMedCrossRef Sargent R, LiVolsi V, Murphy J, et al (2006) BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr Pathol 17:235–241PubMedCrossRef
93.
Zurück zum Zitat Sheils OM, O’Eary J J, Uhlmann V, et al (2000) ret/PTC-1 Activation in Hashimoto thyroiditis. Int J Surg Pathol 8:185–189PubMedCrossRef Sheils OM, O’Eary J J, Uhlmann V, et al (2000) ret/PTC-1 Activation in Hashimoto thyroiditis. Int J Surg Pathol 8:185–189PubMedCrossRef
Metadaten
Titel
Do Benign Thyroid Nodules Have Malignant Potential? An Evidence-Based Review
verfasst von
Nimmi Arora
Theresa Scognamiglio
Baixin Zhu
Thomas J. Fahey III
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 7/2008
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-008-9484-1

Weitere Artikel der Ausgabe 7/2008

World Journal of Surgery 7/2008 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.